×

After-hours buzz: ORCL, AGIO, ADBE & more

People pass by the New York Stock Exchange.
Brendan McDermid | Reuters
People pass by the New York Stock Exchange.

Check out which companies are making headlines after the bell on Thursday:

Oracle shares fell 2 percent after the company released a mixed quarterly report. The technology company posted fiscal second-quarter adjusted earnings per share of 61 cents per share, ex-items, on revenue of $9.07 billion. Analysts had projected Oracle to report earnings of about 60 cents a share on $9.12 billion in revenue, according to a consensus estimate from Thomson Reuters.

Results were dampened slightly by the stronger U.S. dollar for Oracle, which gets little more than half of its revenue from outside the United States. The tech company's financial results come on the heels of a wide-ranging discussion between President-elect Donald Trump and technology CEOs, including Oracle Chief Executive Safra Catz, who was officially added to Trump's transition team on Thursday. Catz will remain at Oracle.

Agios Pharmaceuticals shares plunged more than 18 percent after the company discontinued development of an experimental drug for rare blood disorder due to side effects seen in a study. The side effect was first observed earlier this month at the American Society of Hematology conference, where CEODavid Schenkein spoke with CNBC about the safety of one of the molecules in its drug, which was meant to treat pyruvate kinase deficiency, a rare, genetic anemia.

Shares of Adobe Systems rose slightly after the software company reported fourth-quarter earnings. The company beat on both its top and bottom lines, reporting adjusted earnings of 90 cents a share on a record quarterly revenue of $1.61 billion, representing 23 percent year-over-year revenue growth. Analysts were expecting earnings per share of 86 cents on revenue of $1.59 billion. Its digital media segment revenue was $1.08 billion and creative revenue was $886 million. The company posted a record annual revenue of $5.85 billion in fiscal year 2016.

Gilead Sciences shares fell more than 1 percent after a jury decided it has to pay Merck $2.54 billion in royalties over the patents under its giant Hepatitis C drugs, Sovaldi and Harvoni. The case is tied back to intellectual property that Merck gained in a 2014 acquisition of a biotech company called Identics, spending almost $4 billion to acquire it. Gilead told CNBC it "respectfully disagrees with the jury's verdict and damage award, and intends to vigorously challenge this outcome through the appeal process." If the decision holds, Gilead would regain more than half the price it paid.

—Reuters and CNBC's Anita Balakrishnan and Meg Tirrell contributed to this report.